Edwards Lifesciences Corporation $EW Shares Bought by Mirae Asset Global Investments Co. Ltd.

Key Points

• Mirae Asset Global Investments Co. Ltd. increased its stake in Edwards Lifesciences Corporation by 12.0%, owning 76,157 shares valued at approximately $5.96 million after acquiring 8,144 additional shares.
• Several hedge funds have also adjusted their positions in Edwards Lifesciences, with institutional investors now owning 79.46% of the stock.
• Analysts have raised their price targets for Edwards Lifesciences, with an average consensus target of $86.61 and multiple firms issuing "strong-buy" ratings.

Mirae Asset Global Investments Co. Ltd. increased its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 12.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,157 shares of the medical research company's stock after acquiring an additional 8,144 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in Edwards Lifesciences were worth $5,956,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its position in shares of Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after buying an additional 145 shares in the last quarter. Pacific Capital Partners Ltd acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at about $1,760,000. Czech National Bank increased its holdings in Edwards Lifesciences by 5.8% during the 2nd quarter. Czech National Bank now owns 143,385 shares of the medical research company's stock valued at $11,214,000 after acquiring an additional 7,917 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Edwards Lifesciences by 13.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after acquiring an additional 9,188 shares during the last quarter. Finally, Dynamic Advisor Solutions LLC lifted its holdings in shares of Edwards Lifesciences by 2.4% in the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock valued at $1,124,000 after purchasing an additional 370 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on EW shares. Daiwa America raised shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 29th. Argus raised Edwards Lifesciences to a "strong-buy" rating in a research report on Thursday, July 10th. Royal Bank Of Canada boosted their price target on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. William Blair upgraded Edwards Lifesciences to a "strong-buy" rating in a research report on Friday, July 25th. Finally, Evercore ISI lifted their price objective on Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a research report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $86.61.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $77.03 on Monday. The business has a fifty day simple moving average of $78.50 and a 200-day simple moving average of $76.01. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00. The company has a market cap of $45.22 billion, a P/E ratio of 11.08, a P/E/G ratio of 3.71 and a beta of 1.05. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the company earned $0.70 EPS. The firm's quarterly revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares of the company's stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.